Xenon Pharmaceuticals Inc. $XENE
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS9
PHASE 3 / 2-38
RECRUITING2
READOUTS ≤12 MONTHS3
READOUT SLIPPED >6 MO44%
Delay Index: of 9 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +2.0 months). See all sponsors →
Open Xenon Pharmaceuticals Inc. on the live radar map → 📅 $XENE readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| X-TOLE NCT03796962 |
P2 | Active, not recruiting | Focal Epilepsy | 325 | 2021-09-02 (+14 mo) |
| X-NOVA2 NCT06775379 |
P3 | Active, not recruiting | Major Depressive Disorder | 450 | 2026-10 (+2 mo) |
| X-NOVA-OLE NCT06922110 |
P3 | Active, not recruiting | Major Depressive Disorder | 460 | 2027-01 |
| X-ACKT NCT05667142 |
P3 | Recruiting | Primary Generalized Tonic-Clonic Seizures | 160 | 2027-04 (+22 mo) |
| X-NOVA3 NCT07076407 |
P3 | Active, not recruiting | Major Depressive Disorder | 450 | 2027-05 |
| XEN1101 NCT05716100 |
P3 | Recruiting | Focal Onset Seizures | 360 | 2028-01 (+29 mo) |
| X-CEED NCT07172516 |
P3 | Active, not recruiting | Bipolar Disorder; Bipolar Depression | 400 | 2028-06 |
| Azetukalner NCT07217860 |
P3 | Active, not recruiting | Bipolar Depression; Bipolar I Disorder | 400 | 2029-06 |
| X-TOLE4 NCT05718817 |
P3 | Enrolling by invitation | Focal Epilepsy; Tonic-Clonic Seizures | 880 | 2033-04 (+82 mo) |